Auvi Labs

Cover Block

PUBLIC

Field	Value
Name	Auvi Labs
Tagline	Non-invasive wearable for early detection of dialysis access failure
Headquarters	Chicago, United States
Founded	2024
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech (vascular access monitoring)
Technology Type	Wearable ultrasound hardware
Geography	North America
Growth Profile	Venture Scale (early)
Founding Team	Rishab Veldur (Co-Founder, CEO)
Funding Label	Seed
Total Disclosed	~$101,000

Links

PUBLIC

• Website: https://www.auvilabs.com/
• LinkedIn: https://www.linkedin.com/company/auvilabs
• Founder LinkedIn (Rishab Veldur): https://www.linkedin.com/in/rishab-veldur/

Executive Summary

PUBLIC

Auvi Labs is a Chicago-based healthtech company building Beacon, a wearable ultrasound patch designed to give dialysis patients and their clinicians early warning when vascular access sites begin to fail [Auvi Labs] [ZoomInfo]. The company was founded in 2024 and is led by Co-Founder and CEO Rishab Veldur, a University of Illinois alumnus with a software engineering background [PitchBook] [LinkedIn]. The premise is narrow but clinically meaningful: access failures (thrombosis and stenosis in fistulas and grafts) are a leading cause of unplanned hospitalization for the roughly half-million Americans on hemodialysis, and current monitoring relies on episodic clinic visits rather than continuous, at-home signal. Auvi has disclosed a $101,000 seed round to advance the device and its monitoring platform [Leads on Trees]. The product is positioned as a 10-minute-per-day patient-applied patch, which, if the form factor holds up under clinical validation, would represent a materially lighter compliance burden than existing implantable or continuous-wear monitoring approaches [Delta: HealthTech Innovators Podcast]. Early external validation includes pitch competition wins represented by the founder [Yasmeen Butt LinkedIn] [Paul Magelli LinkedIn]. Over the next 12 to 18 months, the relevant signals will be the build-out of clinical advisors and engineering staff, any pre-submission engagement with the FDA on a Class II pathway, and a priced institutional seed extension that establishes a credible valuation reference.

Data Accuracy: YELLOW -- Founding year and product description corroborated by PitchBook, Crunchbase, and the company website; funding figure cited by a single secondary source (Leads on Trees) and not yet confirmed by Crunchbase or PitchBook.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software (device plus monitoring platform)
Industry / Vertical	Healthtech, nephrology and vascular access
Technology Type	Wearable ultrasound
Geography	North America (Chicago HQ)
Growth Profile	Venture Scale (early-stage)
Founding Team	Solo named founder, Rishab Veldur
Funding	~$101,000 disclosed seed

Company Overview

PUBLIC

Auvi Labs was incorporated in 2024 and operates out of Chicago [PitchBook]. The company describes itself, on its own site, as building "a non-invasive wearable designed for the early detection of dialysis access failure" [Auvi Labs]. The founding context is collegiate and competition-driven: founder Rishab Veldur represented the company at a pitch event affiliated with the University of Illinois, where Auvi placed second in a presentation competition [Paul Magelli LinkedIn], and at a separate competition where the wearable ultrasound device took first place [Yasmeen Butt LinkedIn]. That pattern (university affiliation, competition traction, then a small priced round) is a familiar early arc for medical device spinouts and is consistent with the disclosed seed size.

The key milestone to date is the $101,000 seed round reported in 2024, characterized in the press summary as the company's initial funding intended to advance its monitoring solution [Leads on Trees]. Crunchbase and ZoomInfo independently list the company with the same product framing (a wearable plus monitoring platform that alerts clinicians) but neither has surfaced additional rounds, an institutional lead investor, or board composition [Crunchbase] [ZoomInfo]. The website lists Kevin Volkema, DO, MBA among affiliated names [Auvi Labs], suggesting at least one clinician relationship has been formalized, though the depth of that involvement is not publicly described.

Legal entity details, exact incorporation state, and any IP filings are not publicly available in the captured sources. Investors evaluating the company should expect to verify those directly with the founder.

Data Accuracy: YELLOW -- Founding year and HQ confirmed by PitchBook and the company website; round size cited by a single secondary source.

Product and Technology

MIXED

The product is Beacon, described by the company as a non-invasive wearable for early detection of dialysis access failure [Auvi Labs]. Independent listings characterize the system as a wearable plus monitoring platform that detects access issues and alerts clinicians so that interventions can occur earlier than the current standard of episodic in-clinic surveillance [Crunchbase] [ZoomInfo]. On the Delta: HealthTech Innovators podcast, the device is described more specifically as "a wearable ultrasound patch that patients can use for just 10 minutes a day to detect early signs of access failure" [Delta: HealthTech Innovators Podcast]. A separate description from a community member calls it a "wearable ultrasound device to measure blood flow," which is consistent with the clinical mechanism most commonly used to detect stenosis and thrombosis in arteriovenous fistulas and grafts [Yasmeen Butt LinkedIn].

Mechanistically, this places Beacon in the category of patient-applied diagnostic ultrasound, a form factor that has become more feasible in the last several years as ultrasound transducers have miniaturized and as on-device signal processing has improved. The differentiation, as publicly framed, rests on three claims: that it is non-invasive (no implant, in contrast to certain continuous flow sensors that sit at or near the access site), that it is patient-applied for short daily sessions rather than continuously worn, and that the data feeds a clinician-facing monitoring layer. The clinical validation status, regulatory pathway (most likely 510(k) Class II for a hemodynamic monitor, inferred from category norms rather than confirmed by the company), and any peer-reviewed performance data are not publicly disclosed in the captured sources.

The technology stack beyond the device itself (cloud platform, EHR integration, alerting layer) is not described in public materials, and no engineering job postings were surfaced from major ATS hosts that would allow inference about the back-end architecture. Investors should treat the product as pre-market and pre-clearance until the company publishes otherwise.

Data Accuracy: ORANGE -- Product description corroborated across the company website, Crunchbase, ZoomInfo, and a podcast appearance, but no independent clinical or regulatory documentation is yet public.

Market Research and Opportunity

PUBLIC

Dialysis access monitoring is a small but clinically painful niche inside a very large nephrology spend base, and it is one of the few areas in chronic care where a single failure event reliably triggers a hospitalization. The captured sources do not include a third-party TAM figure specific to wearable access monitoring, so the sizing here is built from analogous public data on the underlying patient population and care setting.

In the United States, the dialysis population sits in the mid-hundreds of thousands of patients, the majority on in-center hemodialysis, and vascular access complications are routinely cited in the nephrology literature as the leading cause of morbidity and unplanned hospitalization for this group (analogous market context, US Renal Data System annual reports). Each access intervention (declotting, angioplasty, surgical revision) carries four- to five-figure procedure costs and is frequently preceded by signals (declining flow, recirculation, rising venous pressure) that current surveillance regimes catch late. That gap between "a measurable physiological signal exists" and "current workflow does not catch it in time" is the structural opening Beacon targets.

Demand-side tailwinds are reasonably durable. CMS payment models for end-stage renal disease, including the ETC (ESRD Treatment Choices) model and value-based arrangements with large dialysis operators, push providers toward home modalities and toward avoiding preventable hospitalizations, both of which favor remote monitoring tools that can document earlier intervention. Adjacent or substitute approaches include implantable flow sensors (Alio's category), in-clinic surveillance protocols using duplex ultrasound, and software-only risk stratification from EHR data. Each has trade-offs on invasiveness, capital cost, or signal latency that a patient-applied ultrasound patch could plausibly improve on.

Reference point	Value	Source
Auvi Labs disclosed seed	$101,000	[Leads on Trees]
Founding year	2024	[PitchBook]

the underlying clinical problem is well-documented and reimbursement direction is favorable, but the company has not yet published the device-specific market sizing or pricing assumptions that would let an investor model revenue. Diligence should focus on whether Auvi plans to sell into dialysis operators (DaVita, Fresenius, US Renal Care), into nephrology practices, or direct to payers under a remote patient monitoring code set.

Data Accuracy: ORANGE -- No company-specific market sizing has been published; framing relies on analogous public nephrology context and the single confirmed funding figure.

Competitive Landscape

MIXED

Auvi enters a category where one well-funded incumbent has already defined the "continuous vascular access monitoring" pitch to investors, which sharpens both the comparison and the differentiation Auvi must defend.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Auvi Labs	Patient-applied wearable ultrasound patch for early detection of dialysis access failure	Seed, ~$101,000 disclosed	Non-invasive, 10-minute daily use, clinician-facing alerts	[Auvi Labs] [Leads on Trees] [Delta: HealthTech Innovators Podcast]
Alio	Connected wearable for dialysis patients monitoring hemodynamic and lab-style parameters	Later stage, multi-round venture-backed (per public coverage)	Continuous-wear device with multi-parameter sensing and FDA clearance history	[Crunchbase]

The segment map has three layers. The incumbent layer is Alio, which has been the most visible venture-backed company specifically targeting dialysis patient monitoring and has accumulated both regulatory and commercial mileage that Auvi has not. Adjacent substitutes include implantable or perivascular flow sensors developed by medical device majors and academic spinouts, plus the in-clinic duplex ultrasound surveillance that nephrology practices already perform on a scheduled basis. The challenger layer, where Auvi sits, is populated by small teams betting that miniaturized ultrasound and patient-applied form factors can deliver a clinically useful signal without an implant and without continuous wear.

Auvi's defensible edge today, to the extent one exists at seed stage, is form factor and compliance burden. A 10-minute daily patch is a meaningfully lighter ask of a chronic patient than a continuously worn device, and it sidesteps the regulatory and reimbursement complexity of an implant. That edge is perishable in two ways: a larger competitor can copy the form factor once Auvi publishes clinical data, and the durability of the signal depends on whether patients actually self-apply the device correctly each day, which is an empirical question the company has not yet answered in public.

The exposure is concrete. Alio has a head start on FDA experience and on relationships with the dialysis operator channel, which is unusually concentrated (two operators control the majority of US in-center patients). If those operators standardize on an incumbent monitoring solution before Auvi has a clinical dataset to compete on, the channel narrows quickly. Auvi also does not yet own the clinician workflow layer (EHR integration, nephrologist-facing dashboards), which is where Alio and any health-system-aligned competitor can entrench.

The most plausible 18-month scenario splits on clinical validation. Winner if Auvi publishes a credible pilot showing that Beacon's daily readings predict access failure earlier than standard surveillance, ideally in partnership with a named dialysis operator or academic medical center: in that case the company becomes a credible Series A target and the form-factor advantage compounds. Loser if Auvi reaches mid-2026 without a clinical readout or a regulatory pre-submission on file, in which case a better-capitalized competitor (Alio or a strategic entrant) can close the form-factor gap before Auvi closes the clinical-evidence gap.

Opportunity

PUBLIC

If Beacon works as described and clears the regulatory bar, Auvi has a credible path to becoming the default at-home surveillance layer for one of the most expensive chronic disease populations in US healthcare.

The headline opportunity. The single largest outcome Auvi could plausibly become is the standard remote monitoring device shipped with every new dialysis access in the United States, billed under existing remote physiologic monitoring code families and integrated into the value-based contracts that the largest dialysis operators are already signing under CMS's ESRD Treatment Choices framework. The reason that outcome is reachable rather than aspirational is that the clinical problem is concentrated (a small number of operators touch most patients), the payment direction is set (operators are penalized for preventable hospitalizations), and the device category Auvi is targeting (patient-applied diagnostic ultrasound) has become technically feasible in a way it was not five years ago [Auvi Labs] [Delta: HealthTech Innovators Podcast].

Growth scenarios

Scenario	What happens	Catalyst	Why it's plausible
Operator standardization	A top-two dialysis operator pilots Beacon, then standardizes for new access patients	A published pilot showing earlier detection vs. standard surveillance	Operator economics already reward avoided hospitalizations under ETC [Auvi Labs]
RPM reimbursement play	Nephrology practices adopt Beacon and bill remote physiologic monitoring codes	FDA clearance plus a CPT-aligned data cadence	The 10-minute daily protocol fits existing RPM time thresholds [Delta: HealthTech Innovators Podcast]
Strategic acquisition	A medical device major or dialysis operator acquires Auvi to own the monitoring layer	Competitive pressure from Alio or an implant entrant	Vascular access monitoring is a named priority category for the listed competitor set [Crunchbase]

What compounding looks like. The flywheel for a device like Beacon is data-driven rather than network-driven. Each additional patient-day of recorded ultrasound signal, paired with eventual access-failure outcomes, sharpens the predictive model that decides when to alert a clinician. Better alerts reduce false positives, which is the single biggest reason clinicians abandon remote monitoring tools, which in turn protects the next operator contract. None of this flywheel is yet in motion publicly, but the architecture for it is implicit in the company's framing of Beacon as a wearable plus monitoring platform [Crunchbase] [ZoomInfo].

The size of the win. A useful comparable is the trajectory of remote cardiac monitoring companies that built on top of CMS RPM codes and were ultimately acquired or scaled into nine-figure revenue businesses; the dialysis access market is smaller in patient count but higher in per-patient acuity and per-event cost. If Auvi reaches the operator-standardization scenario above, a category outcome in the high hundreds of millions of dollars of enterprise value is within the range of public comparables in connected medical devices (scenario, not a forecast). The realistic near-term win, however, is far more modest: a priced institutional seed or seed-extension that validates the team and funds a first clinical study.

Data Accuracy: ORANGE -- Scenarios constructed from cited product description and publicly known reimbursement and operator structure; no company-issued forecasts are public.

Sources

PUBLIC

1. [Auvi Labs] Auvi Labs, Wearable Ultrasound for Vascular Access | https://www.auvilabs.com/

2. [Auvi Labs] About Auvi Labs, Team & Advisors | https://auvilabs.com/about

3. [PitchBook] Auvi Labs 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/688646-26

4. [Crunchbase] Auvi Labs - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/auvi-labs

5. [ZoomInfo] Auvi Labs - Overview, News & Similar companies | https://www.zoominfo.com/c/auvi-labs-inc/1339078779

6. [ZoomInfo] Auvi Labs: Employee Directory | https://www.zoominfo.com/pic/auvi-labs-inc/1339078779

7. [Leads on Trees] Auvi Labs Raises $101K Seed Funding to Advance Dialysis Access Monitoring | https://www.leadsontrees.com/news/auvi-labs-raises-101k-seed-funding-to-advance-dialysis-access-monitoring

8. [LinkedIn] Rishab Veldur - Auvi Labs | https://www.linkedin.com/in/rishab-veldur/

9. [LinkedIn] Auvi Labs company page | https://www.linkedin.com/company/auvilabs

10. [Yasmeen Butt LinkedIn] Yasmeen Butt - Founders Village | https://www.linkedin.com/in/yasmeenbutt/

11. [Paul Magelli LinkedIn] Paul Magelli - Greater Chicago Area | https://www.linkedin.com/in/paulmagelli/

12. [Apple Podcasts] Delta: HealthTech Innovators - Podcast | https://podcasts.apple.com/us/podcast/delta-healthtech-innovators/id1703827145